Physician profile
John H Barton
NPI 1467407429
$285.42
in general payments reported to CMS, 2019-2025
12 companies · $35.80 in 2025
The $35.80 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $20.21 · 2023: $12.84 · 2024: $30.54 · 2025: $35.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.95 · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.95 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66.24 | 2019 | |
| Amgen INC. | $34.76 | 2019 | |
| Lilly USA, LLC | $26.18 | 2019 | |
| Tesaro, INC. | $25.47 | 2019 | |
| Beigene USA, INC. | $21.31 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $20.21 | 2020 | |
| Merck Sharp & Dohme LLC | $17.72 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Tazverik, Onivyde |
| Genentech USA, INC. | $15.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.49 | 2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $14.31 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.84 | 2023 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.